Paper36677483
Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients.
Brandolini M and 13 others. Microorganisms, 2023. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients. Papers, record 36677483. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36677483
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35752633 | Detection of SARS-CoV-2 intra-host recombination during superinfection with Alpha and Epsilon variants in New York City. | Nat Commun | 2022 | https://conductscience.org/library/papers/35752633 | PubMed |
| 2 | 19016439 | Growth and maintenance of Vero cell lines. | Curr Protoc Microbiol | 2008 | https://conductscience.org/library/papers/19016439 | PubMed |
| 3 | 35450114 | Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection. | Infect Drug Resist | 2022 | https://conductscience.org/library/papers/35450114 | PubMed |
| 4 | 33619260 | SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. | NPJ Vaccines | 2021 | https://conductscience.org/library/papers/33619260 | PubMed |
| 5 | 36109713 | SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia. | BMC Med | 2022 | https://conductscience.org/library/papers/36109713 | PubMed |
| 6 | 34035118 | SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. | Sci Immunol | 2021 | https://conductscience.org/library/papers/34035118 | PubMed |
| 7 | 35419806 | The recombinant variants of SARS-CoV-2: Concerns continues amid COVID-19 pandemic. | J Med Virol | 2022 | https://conductscience.org/library/papers/35419806 | PubMed |
| 8 | 35271316 | COVID-19 vaccination: The road ahead. | Science | 2022 | https://conductscience.org/library/papers/35271316 | PubMed |
| 9 | 35597776 | Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. | Sci Rep | 2022 | https://conductscience.org/library/papers/35597776 | PubMed |
| 10 | 35746710 | Recombination in Coronaviruses, with a Focus on SARS-CoV-2. | Viruses | 2022 | https://conductscience.org/library/papers/35746710 | PubMed |
| 11 | 33684923 | Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. | Nature | 2021 | https://conductscience.org/library/papers/33684923 | PubMed |
| 12 | 34192737 | Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. | Nature | 2021 | https://conductscience.org/library/papers/34192737 | PubMed |
| 13 | 32585083 | An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. | Curr Protoc Microbiol | 2020 | https://conductscience.org/library/papers/32585083 | PubMed |
| 14 | 35130825 | A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. | Hum Vaccin Immunother | 2022 | https://conductscience.org/library/papers/35130825 | PubMed |
| 15 | 33479399 | COVID-19 vaccines: where we stand and challenges ahead. | Cell Death Differ | 2021 | https://conductscience.org/library/papers/33479399 | PubMed |
| 16 | 17868000 | IFCC position paper: report of the IFCC taskforce on ethics: introduction and framework. | Clin Chem Lab Med | 2007 | https://conductscience.org/library/papers/17868000 | PubMed |
| 17 | 35864211 | Mutational induction in SARS-CoV-2 major lineages by experimental exposure to neutralising sera. | Sci Rep | 2022 | https://conductscience.org/library/papers/35864211 | PubMed |
| 18 | 32458296 | On the Calculation of TCID50 for Quantitation of Virus Infectivity. | Virol Sin | 2021 | https://conductscience.org/library/papers/32458296 | PubMed |
| 19 | 34647020 | Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination. | Clin Pathol | 2021 | https://conductscience.org/library/papers/34647020 | PubMed |
| 20 | 33536258 | Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. | Science | 2021 | https://conductscience.org/library/papers/33536258 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41299695 | The virology of Omicron: pathophysiology, immune regulation, and clinical impact of SARS-CoV-2 sub variants. | Virol J | 2025 | https://conductscience.org/library/papers/41299695 | PubMed |
| 41234640 | SARS-CoV-2 mRNA vaccine candidate encoding RBD chimera of Delta and Omicron variants: immunogenic potential and validation. | Iran J Microbiol | 2025 | https://conductscience.org/library/papers/41234640 | PubMed |
| 41011531 | Neutralizing Antibodies vs. Viruses: Interacting Mechanisms and Escape Tactics. | Microorganisms | 2025 | https://conductscience.org/library/papers/41011531 | PubMed |
| 40145092 | The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells. | Front Immunol | 2025 | https://conductscience.org/library/papers/40145092 | PubMed |
| 39499071 | Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk. | J Virol | 2024 | https://conductscience.org/library/papers/39499071 | PubMed |
| 39323472 | Structural and genomic evolutionary dynamics of Omicron variant of SARS-CoV-2 circulating in Madhya Pradesh, India. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/39323472 | PubMed |
| 39179492 | Worldwide SARS-CoV-2 Omicron variant infection: Emerging sub-variants and future vaccination perspectives. | J Formos Med Assoc | 2025 | https://conductscience.org/library/papers/39179492 | PubMed |
| 37560529 | The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2. | Front Microbiol | 2023 | https://conductscience.org/library/papers/37560529 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36677483
GET https://conductscience.org/api/papers/v1/36677483/references?page=2